[Intravitreal bevacizumab in neovascularisation secondary to age-related macular degeneration].
Ordóñez Fernández
L
L
Celemín Viñuela
M L
ML
Fernández Lisa
C
C
García Alonso
A
A
Fonolla Gil
M
M
Fernández Bustillo
E
E
D000367:Age Factors; D000368:Aged; D000375:Aging / Q000502:physiology*; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005260:Female; D006801:Humans; D008268:Macular Degeneration / Q000150:complications*; D008297:Male; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000209:etiology*; D012189:Retrospective Studies; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab